Plain language summary of the himalaya study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
Publication date:
2023
Publisher version:
Citación:
Future Oncology, 19(38) (2023); doi:10.2217/fon-2023-0486
Files in this item
